source
- BMS drops Orum’s targeted degrader after Phase 1 resultsBMS announced it is ending development of ORM-6151, a degrader‑antibody conjugate acquired from Orum Therapeutics. The decision follows a Phase 1 trial in acute myeloid leukemia and myelodysplasti…
- FDA updates instructions for NOxBOXi nitric oxide delivery system after leak risk identifiedThe FDA has issued a correction for the NOxBOXi nitric oxide delivery system with the NOxMixer module after discovering that the device can leak oxygen during inhaled nitric oxide therapy. The age…